When the number crunchers released their 2011 venture analyses earlier this year, they sparked debate about just how bad – or perhaps good – the fundraising environment for start-up biotechs really was. Read More
C3 Jian Inc. has found funding from an unusual place: Three Delta Dental member companies contributed $30 million to help the biotech develop C16G2, a peptide drug targeting the bacteria that cause dental cavities, and the rest of its oral health pipeline. Read More
